IM8N Stock Overview A biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Insmed Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for Insmed Historical stock prices Current Share Price US$72.00 52 Week High US$72.00 52 Week Low US$20.00 Beta 1.11 1 Month Change 5.11% 3 Month Change n/a 1 Year Change n/a 3 Year Change 202.52% 5 Year Change 236.45% Change since IPO 906.99%
Recent News & Updates Insmed Incorporated has withdrawn its Follow-on Equity Offering in the amount of $500 million. Nov 19
Insmed Incorporated Reiterates earnings Guidance for the Year 2024 Nov 01
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$1.11 loss in 3Q 2023) Nov 01
Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results Oct 09
Insufficient new directors Oct 08 See more updates Insmed Incorporated has withdrawn its Follow-on Equity Offering in the amount of $500 million. Nov 19
Insmed Incorporated Reiterates earnings Guidance for the Year 2024 Nov 01
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$1.11 loss in 3Q 2023) Nov 01
Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results Oct 09
Insufficient new directors Oct 08
Chief People Strategy Officer recently sold €628k worth of stock Aug 15
Second quarter 2024 earnings released: US$1.94 loss per share (vs US$1.78 loss in 2Q 2023) Aug 09
New major risk - Revenue and earnings growth Aug 09
Insmed Incorporated Reiterates Revenue Guidance for the Year 2024 Aug 08
Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024 Jul 29
Insmed Incorporated Announces Additional Positive Results from the ASPEN Study Jul 04 Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million. May 31
Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million. Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session
Insufficient new directors May 17
Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024 Apr 27
Insmed Incorporated, Annual General Meeting, May 13, 2024 Apr 02
Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference Mar 28
Insufficient new directors Mar 14
Full year 2023 earnings released: US$5.34 loss per share (vs US$3.91 loss in FY 2022) Feb 23 Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million. Feb 22
Insufficient new directors Feb 12
Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024 Feb 09
Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024 Jan 05
Third quarter 2023 earnings released: US$1.11 loss per share (vs US$1.09 loss in 3Q 2022) Oct 27
Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023 Oct 13
Insufficient new directors Sep 11
Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac Sep 06 Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd. Aug 05
Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Insufficient new directors Jun 06
Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference May 24
Senior VP recently sold €63k worth of stock May 19 Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event
Insufficient new directors May 08
Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023 May 05
Insufficient new directors Mar 22
Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021) Feb 25
Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023 Feb 10
Insufficient new directors Jan 18
Insufficient new directors Dec 02
Chief Operating Officer recently sold €217k worth of stock Nov 24
Independent Director recently bought €805k worth of stock Nov 04
Third quarter 2022 earnings released: US$1.09 loss per share (vs US$0.96 loss in 3Q 2021) Oct 28
Insmed Incorporated Provides Revenue Guidance for the Year 2022 Oct 28 Insmed Incorporated announced that it expects to receive $625 million in funding Oct 20
Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Second quarter 2022 earnings released: US$0.80 loss per share (vs US$1.07 loss in 2Q 2021) Aug 05
Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022 Aug 05
Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Insmed Incorporated Names Drayton Wise as Chief Commercial Officer May 24
Independent Director recently bought €326k worth of stock May 15
First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.89 loss in 1Q 2021) May 06
Insmed Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Insmed Incorporated, Annual General Meeting, May 11, 2022 Apr 02
Insmed Incorporated Provides Earnings Guidance for the Full Year 2022 Feb 18
Insmed Incorporated to Report Q4, 2021 Results on Feb 17, 2022 Jan 28
High number of new directors Nov 17
High number of new directors Oct 11 Insmed Incorporated Unable to Provides Revenue Guidance Due to Covid Jun 10
Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $250 million. May 12
First quarter 2021 earnings released: US$0.89 loss per share (vs US$0.74 loss in 1Q 2020) May 07
Independent Director recently bought €83k worth of stock Mar 11
Full year 2020 earnings released: US$3.01 loss per share (vs US$3.01 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) Feb 20
Insmed Incorporated to Report Q4, 2020 Results on Feb 25, 2021 Feb 13 Shareholder Returns IM8N DE Biotechs DE Market 7D 0% -2.9% -2.6% 1Y n/a -14.7% 6.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how IM8N performed against the German Market .
Price Volatility Is IM8N's price volatile compared to industry and market? IM8N volatility IM8N Average Weekly Movement n/a Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IM8N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine IM8N's volatility change over the past year.
About the Company Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
Show more Insmed Incorporated Fundamentals Summary How do Insmed's earnings and revenue compare to its market cap? IM8N fundamental statistics Market cap €12.08b Earnings (TTM ) -€828.33m Revenue (TTM ) €328.69m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IM8N income statement (TTM ) Revenue US$342.96m Cost of Revenue US$78.03m Gross Profit US$264.92m Other Expenses US$1.13b Earnings -US$864.28m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.83 Gross Margin 77.25% Net Profit Margin -252.01% Debt/Equity Ratio 230.6%
How did IM8N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 16:33 End of Day Share Price 2024/12/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Insmed Incorporated is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Neena Bitritto-Garg Baird Leon Wang Barclays Anita Dushyanth Berenberg
Show 30 more analysts 
